InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: ku post# 274066

Saturday, 10/01/2016 12:13:22 AM

Saturday, October 01, 2016 12:13:22 AM

Post# of 345732
KU... Peregrine and K&L Gates I am sure can devise a plan ....not sure if they have to be a little creative or not ...but just off the top of my head:

a plan for Peregrine legal to approach a deal with one other Big Pharma that just may be a nice little loophole around some things of concern ...

1) Peregrine signs over their PS Targeting rights to....possible ....some very interested Big Pharma and simply just need to add some clauses..

Those PS Targeting rights are then transferred back to Peregrine under a longterm license deal (will add additional clauses here...) and ultimately now it does not matter if someone owns 50% of PPHM because the other Big Pharma party now has the PS Targeting rights and all Peregrine has is the sole license from them them to do as they please...

Again, many clauses I leave out re: monies and cash and stock ...

For example: many of the clauses could be worked out all based upon what PPHM pps does and how it reacts or how little or how much it was to be manipulated

IF PPHM continued to be kept low, the other Big Pharma could be positioned to set up large multiple upfront cash payments (to offset any manipulation) and in return would be granted some cheap ($5 pps PPHM stock..etc) and the goal being that in time with large cash reserves the stock WOULD NOT be kept under a $1

New Preferred shares ... exchanges could be formed and each side can be capped once the correct percentages and cash/stock are finally all reached

The goal here is whomever may have 50% of PPHM now will have no immediate threat to Peregrine because the patents are transferred to the other party and ok... Maybe I am overthinking all this but I will always believe there is a way around things and if KL Gates brought Preferred Shares to the table I am certain the table is ready with more of the same success to follow



"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News